{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:17:15Z","timestamp":1793175435032,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T00:00:00Z","timestamp":1363824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1208\/s12249-013-9949-x","type":"journal-article","created":{"date-parts":[[2013,3,20]],"date-time":"2013-03-20T21:14:06Z","timestamp":1363814046000},"page":"639-648","source":"Crossref","is-referenced-by-count":12,"title":["Formulation and Development of Extended-Release Micro Particulate Drug Delivery System of Solubilized Rifaximin"],"prefix":"10.1208","volume":"14","author":[{"given":"Rohan V.","family":"Karanje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita V.","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti H.","family":"Jahagirdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran S.","family":"Bhise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,21]]},"reference":[{"issue":"9","key":"9949_CR1","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.bmc.2004.02.027","volume":"12","author":"S Martini","year":"2004","unstructured":"Martini S et al. Solution structure of rifaximin and its synthetic derivative rifaximin determined by experimental NMR and theoretical simulation methods. Bioorg Med Chem. 2004;12(9):2163\u201372. doi: 10.1016\/j.bmc.2004.02.027 .","journal-title":"Bioorg Med Chem"},{"key":"9949_CR2","doi-asserted-by":"crossref","unstructured":"Huang DB, DuPont HL. Rifaximin\u2014a novel antimicrobial for enteric infections. J Infect. 50(2): 97\u2013106.","DOI":"10.1016\/j.jinf.2004.05.019"},{"key":"9949_CR3","unstructured":"Jahagirdar HA. Patent Application No- 20090028940 USPC CLASS: 424468 NO DOI FOR PATENT."},{"issue":"suppl 1","key":"9949_CR4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","volume":"51","author":"C Scarpignato","year":"2005","unstructured":"Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51 suppl 1:36\u201366. doi: 10.1159\/000081990 .","journal-title":"Chemotherapy"},{"key":"9949_CR5","doi-asserted-by":"crossref","unstructured":"Vaira D. Rifaximin suspension for the eradication of Helicobacter pylori. Curr Ther Res. 58(5):300\u2013308.","DOI":"10.1016\/S0011-393X(97)80027-6"},{"key":"9949_CR6","doi-asserted-by":"crossref","unstructured":"Darkoh C et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob agents chemother. 2010;3618\u20133624. doi: 10.1128\/AAC.00161-10 .","DOI":"10.1128\/AAC.00161-10"},{"key":"9949_CR7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2003.10.020","volume":"57","author":"S Rawat","year":"2004","unstructured":"Rawat S, Jain SK. Solubility enhancement of celecoxib using \u03b2-cyclodextrin inclusion complexes. Eur J Pharm Biopharm. 2004;57:263\u20137. doi: 10.1016\/j.ejpb.2003.10.020 .","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"9949_CR8","first-page":"1098","volume":"2","author":"N Bidyut","year":"2010","unstructured":"Bidyut N, Amrutansu P, Annapurna MM. Spectrophotometric estimation of rifaximin in pure and tablet dosage form. Int J Pharm Technol. 2010;2(4):1098\u2013104.","journal-title":"Int J Pharm Technol"},{"key":"9949_CR9","doi-asserted-by":"crossref","unstructured":"Loftsson T, Vogensen SB, Desbos C, Jansook P. Carvedilol: solubilization and cyclodextrin complexation: a technical note. AAPS PharmSciTech. 2008;9(2) (# 2008). doi: 10.1208\/s12249-008-9055-7 .","DOI":"10.1208\/s12249-008-9055-7"},{"issue":"2","key":"9949_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1208\/s12249-008-9078-0","volume":"9","author":"AR Patel","year":"2008","unstructured":"Patel AR, Vavia PR. Preparation and evaluation of taste masked famotidine formulation using drug\/\u03b2-cyclodextrin\/polymer ternary complexation approach. AAPS PharmSciTech. 2008;9(2):544\u201350. doi: 10.1208\/s12249-008-9078-0 .","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"9949_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0939-6411(02)00166-2","volume":"55","author":"KJ Waleczeka","year":"2003","unstructured":"Waleczeka KJ, Cabral Marquesb HM, Hempelc B, Schmidt PC. Phase solubility studies of pure (2)-a-bisabolol and camomile essential oil with b-cyclodextrin. Eur J Pharm Biopharm. 2003;55(2):247\u201351. doi: 10.1016\/S0939-6411(02)00166-2 .","journal-title":"Eur J Pharm Biopharm"},{"key":"9949_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-409X(98)00058-1","volume":"36","author":"F Hirayama","year":"1999","unstructured":"Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36:125\u201341. doi: 10.1016\/S0169-409X(98)00058-1 .","journal-title":"Adv Drug Deliv Rev"},{"key":"9949_CR13","doi-asserted-by":"crossref","unstructured":"Liu L et al. A study on the supramolecular structure of inclusion complex of \u03b2-cyclodextrin with prazosin hydrachloride. Carbohydrate polymers, 68(Issue 3):472\u2013476. doi: 10.1016\/j.carbpol.2006.11.007 .","DOI":"10.1016\/j.carbpol.2006.11.007"},{"key":"9949_CR14","doi-asserted-by":"crossref","unstructured":"Werner F, Okemo P, Ansorg R. Antibacterial activity of East African Medicinal; plants. J Ethnopharmacol. 60:79\u201384.","DOI":"10.1016\/S0378-8741(97)00128-1"},{"key":"9949_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3797\/scipharm.2007.75.63","volume":"75","author":"FK Alanazi","year":"2007","unstructured":"Alanazi FK, El-Badry M, Ahmed MO, Alsarra IA. Improvement of albendazole dissolution by preparing microparticles using spray-drying technique. Sci Pharm. 2007;75:63\u201379.","journal-title":"Sci Pharm"},{"key":"9949_CR16","doi-asserted-by":"crossref","unstructured":"Liu W, Wu WD, Selomulya C, Chen XD. Uniform chitosan microparticles prepared by a novel spray-drying technique. Int J Chem Eng. 2011;2011. doi: 10.1155\/2011\/267218 . Article ID 267218, 7 Pages.","DOI":"10.1155\/2011\/267218"},{"key":"9949_CR17","unstructured":"Robinson S. (Melton Mowbray GB), Smith, Susan Stewart (Leicestershire GB). Spray-drying process for the preparation of microparticles; Application Number: 09\/342356 Patent no: US 6,451,349 B1."},{"key":"9949_CR18","doi-asserted-by":"crossref","unstructured":"Elshafeey AH, Sami EI. Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of Fenoterol Hydrobromide. AAPS PharmSciTech. 2008;9(3) (# 2008). doi: 10.1208\/s12249-008-9135-8 .","DOI":"10.1208\/s12249-008-9135-8"},{"issue":"3","key":"9949_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-4636(20010905)56:3<333::AID-JBM1101>3.0.CO;2-K","volume":"56","author":"P Narayan","year":"2001","unstructured":"Narayan P, Marchant D, Wheatley MA. Optimization of spray drying by factorial design for production of hollow microspheres for ultrasound imaging. J Biomed Mater Res. 2001;56(3):333\u201341. doi: 10.1002\/1097-4636(20010905)56:3333::AID-JBM1101>3.0.CO;2-K .","journal-title":"J Biomed Mater Res"},{"issue":"1\u20132","key":"9949_CR20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2008.09.029","volume":"367","author":"L Tajber","year":"2009","unstructured":"Tajber L, Corrigan OI, Healy AM. Spray drying of budesonide, formoterol fumarate and their composites\u2014II. Statistical factorial design and in vitro deposition properties. Int J Pharm. 2009;367(1\u20132):86\u201396. doi: 10.1016\/j.ijpharm.2008.09.029 .","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-013-9949-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-013-9949-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-013-9949-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T05:12:07Z","timestamp":1562821927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-013-9949-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9949"],"URL":"https:\/\/doi.org\/10.1208\/s12249-013-9949-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,21]]}}}